Posted by Michael Wonder on 21 Jul 2022
Karyopharm and Menarini receive full marketing authorisation from the European Commission for Nexpovio (selinexor) for the treatment of patients with multiple myeloma after at least one prior therapy
21 July 2022 - Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indication.
Karyopharm Therapeutics and the Menarini today announced that the European Commission has granted Marketing Authorisation for Nexpovio (selinexor), a first-in-class, oral exportin 1 inhibitor, in combination with once-weekly bortezomib (Velcade) and low-dose dexamethasone for the treatment of adults with multiple myeloma who have received at least one prior therapy.
